Inhibitors of Platelets Glycoprotein IIb / IIIa (GP IIb / IIIa) Receptor: Rationale for their Use in Clinical Cardiology

Title: Inhibitors of Platelets Glycoprotein IIb / IIIa (GP IIb / IIIa) Receptor: Rationale for their Use in Clinical Cardiology

Volume: 4 Issue: 7

Author(s): M. L. Rossi and D. Zavalloni

Affiliation:

Keywords: platelet aggregation inhibitors, glycoprotein, acute coronary syndromes, atherosclerotic plaque, percutaneous coronary intervention

Abstract: The glycoprotein IIb / IIIa (GP IIb / IIIa) receptor is the most important receptor involved in platelet aggregation. A stable GP IIb / IIIa inhibition is required when a massive platelet activation triggers thrombosis. Three GP IIb / IIIa inhibitors are currently approved for clinical use: abciximab, tirofiban and integrilin. Their different pharmacodynamic and pharmacokinetic properties reflect a different efficacy in platelet inhibition.

Cite this article as:

Rossi L. M. and Zavalloni D., Inhibitors of Platelets Glycoprotein IIb / IIIa (GP IIb / IIIa) Receptor: Rationale for their Use in Clinical Cardiology, Mini-Reviews in Medicinal Chemistry 2004; 4 (7) . https://dx.doi.org/10.2174/1389557043403666